In 2013 and 2014, the partners won orphan drug designation in the US for isavuconazonium for treating invasive aspergillosis, mucormycosis, and invasive candidiasis.In 2014, Basilea and Astellas amended the agreement to give Astellas sole marketing authority in North America, and Basilea the rights to market in the rest of the world.The U.S. Food and Drug Administration (FDA) granted approval in March 2015, and the European Medicines Agency (EMA) approved it in October 2015.In 2017, Basilea licensed rights to Pfizer to market isavuconazole in Europe and other regions. References
External links
"Isavuconazonium". Drug Information Portal. U.S. National Library of Medicine. "Isavuconazonium sulfate". Drug Information Portal. U.S. National Library of Medicine. "Isavuconazole". Drug Information Portal. U.S. National Library of Medicine.
Posterior amorphous corneal dystrophy (PACD) is a rare form of corneal dystrophy. It is not yet linked to any chromosomal locus. The first report describing this dystrophy dates back to 1977. References


== External links ==